TRAIL-based therapy in pediatric bone tumors: how to overcome resistance.
Future Oncol
; 11(3): 535-42, 2015.
Article
em En
| MEDLINE
| ID: mdl-25675131
ABSTRACT
Osteosarcoma and Ewing's sarcoma, the two most frequent malignant primary tumors preferentially arise in children and young adults, and have a poor prognosis. TRAIL represents a promising therapeutic approach for most cancers but in the case of primary bone tumors, osteosarcoma cell lines are highly resistant to this pro-apoptotic cytokine. In addition, another signaling pathway mediating cell proliferation and migration may be even activated in this subset of resistant cells leading to protumoral effect. Therapeutic perspectives are linked to possibility to overcome TRAIL resistance by combining other drugs with TRAIL or death receptors agonistic antibodies. We hypothesized that the bone microenvironment may provide a favorable niche for TRAIL resistance that might be targeted by new resensitizing agents.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Ósseas
/
Transdução de Sinais
/
Ligante Indutor de Apoptose Relacionado a TNF
/
Terapia de Alvo Molecular
/
Antineoplásicos
Tipo de estudo:
Prognostic_studies
Limite:
Child
/
Child, preschool
/
Humans
Idioma:
En
Ano de publicação:
2015
Tipo de documento:
Article